Use of cerebrospinal fluid biomarkers of Alzheimer's disease risk in mild cognitive impairment and subjective cognitive decline in routine clinical care in Germany

Manuscript Number: 

20-0794R1

Author(s): 
Claudia Bartels, Anna Kögel, Michael Pentzek, Silke Schicktanz, Anja Schneider, Mark Schweda, Jens Wiltfang

Disclosures

Claudia Bartels

  • Patents/Royalties
    There are no financial relationships with commercial interests related to this project/article. Beyond that, CB receives honoraria as a diagnostic consultant for Boehringer Ingelheim.

Anna Kögel

  • Nothing to Disclose

Michael Pentzek

  • Nothing to Disclose

Silke Schicktanz

  • Nothing to Disclose

Anja Schneider

  • Nothing to Disclose

Mark Schweda

  • Nothing to Disclose

Jens Wiltfang

  • Consulting Fees:
    Abbott, Biogen, Boehringer Ingelheim, Immungenetics, Lilly, MSD Sharp & Dohme, and Roche Pharma
    Lecture Fees:
    Actelion, Amgen, Helios Klinikum Wuppertal, Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, Vitos Kurhessen-Bad Emstal
    Patents/Royalties
    Patent no.: EP1270592B1; patent no.: US 6,849,416 B2; patent no.: EP2095128B1; patent no.: EP3105589A1